Barinthus Biotherapeutics plc (BRNS)Healthcare | Biotechnology | Germantown, United States | NasdaqGM
0.59 USD
+0.00
(0.017%)
⇧
(April 21, 2026, 10:30 a.m.
EDT)
Short-term: ★★★☆☆ | Long-term: ★★☆☆☆ | Dividends: ☆☆☆☆☆ |
Hot Take | April 19, 2026, 12:22 a.m. EDT
Despite a massive 26% year-to-date rally pushing the stock near its 52-week high, the latest 14-day price action shows distribution and weak momentum as it fails to break above its 50-day average. Fundamentally, the M&A announcement with Clywedog is a neutral catalyst rather than a value driver, given the low equity value of both parties. Forecasts still warn of significant downside risk over the next 45 days, while the balance sheet lacks the transformative growth required for a long-term buy. |
| Model | MAE |
|---|---|
| AutoTheta ✓ | 0.078446 |
| AutoETS | 0.172179 |
| MSTL | 0.172931 |
| AutoARIMA | 0.184394 |
Forecast horizon: 45 days | Selected: AutoTheta
| Forecast Reliability | |
|---|---|
| Score | 76% |
| H-stat | 1.12 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.212 |
| Excess Kurtosis | -1.22 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 15.185 |
| Market Cap | 24,104,930 |
| Forward P/E | -0.51 |
| Beta | -0.60 |
| Previous Name | Vaccitech plc |
| Website | https://www.barinthusbio.com |
| Attribute | Value |
|---|---|
| 52 Week Change | -0.21854305 |
| Address1 | 20,400 Century Boulevard |
| Address2 | Suite 210 |
| All Time High | 17.99 |
| All Time Low | 0.512 |
| Ask | 0.6 |
| Ask Size | 1 |
| Average Daily Volume10 Day | 21,720 |
| Average Daily Volume3 Month | 40,563 |
| Average Volume | 40,563 |
| Average Volume10Days | 21,720 |
| Beta | -0.604 |
| Bid | 0.57 |
| Bid Size | 1 |
| Book Value | 1.817 |
| City | Germantown |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 0.5901 |
| Current Ratio | 7.765 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,774,915,200 |
| Day High | 0.605 |
| Day Low | 0.59 |
| Debt To Equity | 15.185 |
| Display Name | Barinthus Biotherapeutics |
| Earnings Timestamp End | 1,754,569,800 |
| Earnings Timestamp Start | 1,754,569,800 |
| Ebitda | -55,223,000 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | 0.634 |
| Enterprise Value | -34,990,152 |
| Eps Current Year | -1.15 |
| Eps Forward | -1.15 |
| Eps Trailing Twelve Months | -1.64 |
| Esg Populated | 0 |
| Exchange | NGM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 0.6019 |
| Fifty Day Average Change | -0.011799991 |
| Fifty Day Average Change Percent | -0.019604571 |
| Fifty Two Week Change Percent | -21.854305 |
| Fifty Two Week High | 2.92 |
| Fifty Two Week High Change | -2.3299 |
| Fifty Two Week High Change Percent | -0.7979109 |
| Fifty Two Week Low | 0.512 |
| Fifty Two Week Low Change | 0.078099966 |
| Fifty Two Week Low Change Percent | 0.15253899 |
| Fifty Two Week Range | 0.512 - 2.92 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,619,789,400,000 |
| Float Shares | 24,523,224 |
| Forward Eps | -1.15 |
| Forward P E | -0.5131304 |
| Free Cashflow | -28,044,376 |
| Full Exchange Name | NasdaqGM |
| Full Time Employees | 14 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 0.0 |
| Gross Profits | -133,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.13116999 |
| Held Percent Institutions | 0.40881002 |
| Implied Shares Outstanding | 40,848,893 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Barinthus Biotherapeutics plc, together with its subsidiaries, engages in the research, development, and commercialization of immunotherapies and vaccines in the United States and the United Kingdom. The company develops VTP-1000, an antigen-specific immune tolerance candidate, which is in Phase I clinical trial to restore immune non-responsiveness to gluten in patients with celiac disease; and VTP-300, an immunotherapy, which is in Phase II clinical trial for the treatment of chronic hepatitis B virus infection. It has a license agreement with Oxford University Innovation for the development and commercialization of products with thermo-responsive adjuvant scaffolds; and U.S. National Institutes of Health for the evaluation of synthetic and polymer-based vaccine technology to prevent infectious disease and treat cancer in animal models. The company was formerly known as Vaccitech plc and changed its name to Barinthus Biotherapeutics plc in November 2023. Barinthus Biotherapeutics plc was founded in 2016 and is based in Germantown, Maryland. |
| Long Name | Barinthus Biotherapeutics plc |
| Market | us_market |
| Market Cap | 24,104,930 |
| Market State | REGULAR |
| Max Age | 86,400 |
| Message Board Id | finmb_366057508 |
| Most Recent Quarter | 1,767,139,200 |
| Name Change Date | 2,026-04-20 |
| Net Income To Common | -66,428,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 24,100,846 |
| Number Of Analyst Opinions | 2 |
| Open | 0.59 |
| Operating Cashflow | -47,979,000 |
| Operating Margins | 0.0 |
| Payout Ratio | 0.0 |
| Phone | 443 917 0966 |
| Prev Name | Vaccitech plc |
| Previous Close | 0.59 |
| Price Eps Current Year | -0.5131304 |
| Price Hint | 4 |
| Price To Book | 0.3247661 |
| Profit Margins | 0.0 |
| Quick Ratio | 7.163 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Region | US |
| Regular Market Change | 0.000100016594 |
| Regular Market Change Percent | 0.01695484 |
| Regular Market Day High | 0.605 |
| Regular Market Day Low | 0.59 |
| Regular Market Day Range | 0.59 - 0.605 |
| Regular Market Open | 0.59 |
| Regular Market Previous Close | 0.59 |
| Regular Market Price | 0.5901 |
| Regular Market Time | 1,776,781,824 |
| Regular Market Volume | 14,046 |
| Return On Assets | -0.28079998 |
| Return On Equity | -0.65019 |
| Sand P52 Week Change | 0.34445214 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 40,848,893 |
| Shares Percent Shares Out | 0.00029999999 |
| Shares Short | 10,469 |
| Shares Short Previous Month Date | 1,772,150,400 |
| Shares Short Prior Month | 8,036 |
| Short Name | Barinthus Biotherapeutics plc |
| Short Percent Of Float | 0.0004 |
| Short Ratio | 0.31 |
| Source Interval | 15 |
| State | MD |
| Symbol | BRNS |
| Target High Price | 7.0 |
| Target Low Price | 4.0 |
| Target Mean Price | 5.5 |
| Target Median Price | 5.5 |
| Total Cash | 70,456,000 |
| Total Cash Per Share | 1.725 |
| Total Debt | 11,281,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -1.64 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 0.94853 |
| Two Hundred Day Average Change | -0.35843003 |
| Two Hundred Day Average Change Percent | -0.37787947 |
| Type Disp | Equity |
| Volume | 14,046 |
| Website | https://www.barinthusbio.com |
| Zip | 20,874 |